A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Calcipotriene (Calcitrene)

Calcipotriene and Betamethasone Dipropionate Ointment is indicated for the topical treatment of plaque psoriasis in patients 12 years of age and older.

First FDA approval1996-10-01
Generic availableYes · 5 mfrs
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one

$35.6M in CY2024 Part D spend226K claims · 131K beneficiaries · 329 plans surveyed

Lowest NADAC
$1.10/unit
11 NDCs benchmarked, lowest of all strengths.
Average NADAC
$1.65
Across all dosage forms in distribution.
Highest NADAC
$2.69
Range is tight.
Plans with PA
265 / 329
Limited PA friction.

Questions a plan sponsor actually asks.

FAQPage schema11 entries indexed · 4 visible
What is Calcipotriene used for?

Calcipotriene and Betamethasone Dipropionate Ointment is indicated for the topical treatment of plaque psoriasis in patients 12 years of age and older.

Is there a generic for Calcipotriene?

Yes. 5 ANDAs filed at FDA, 5 generic manufacturers currently shipping.

How much does my plan pay for Calcipotriene?

Across 329 Part D plans, Calcipotriene averages $1.65/unit (NADAC). Lowest available: $1.10/unit. Highest in distribution: $2.69/unit.

Is Calcipotriene on the FDA shortage list?

No. Calcipotriene is not currently on the FDA Drug Shortage Database.

7 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Same class. Different math.

Vitamin D Analog2 alternatives in D1
01
Calcipotriene and Betamethasone Dipropionate
Brand: ENSTILAR
$0.886Lowest NADAC
3Generic mfrs
CY24 Part D spend
Compare →
02
Calcipotriene, Betamethasone Dipropionate
Brand: Calcipotriene and Betamethasone Dipropionate
$1.72Lowest NADAC
0Generic mfrs
CY24 Part D spend
Compare →

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (8 approvals on file) · NADAC unit costs: CMS NADAC weekly file (11 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.